Noticeable Stock: Mountain High Acquisitions Corp (MYHI), Nemus Bioscience Inc (NMUS), Earth Science Tech Inc (ETST)
Mountain High Acquisitions Corp (OTCMKTS:MYHI) showing jumped of 3.07% and closed at $0.205, after gaining total volume of 448,634.00 shares. Its earnings per share (EPS) is -$0.02 and its beta value stands at 3.19 points and has total market capitalization of $11.82 million and a total of 58.05 million outstanding shares.
Mountain High Acquisitions Corp. is a holding company. The Company is focused on the commercial hemp and Cannabidiol (CBD) products industries. The Company is a real estate investment firm whose primary focus was to hold, develop and manage real property. The Company focuses on acquiring and equipping commercial facilities to be leased to and utilized by the commercial marijuana industry in Colorado. The Company’s subsidiaries include Greenlife BiotanX, Inc., Canna-Life Corporation (Canna-Life) and Freedom Feed & Seed Inc. Greenlife BiotanX, Inc. is engaged in developing and marketing of cosmetics. Greenlife BiotanX, Inc. offers various products, including face creams, anti-aging serum and body lotions.
Nemus Bioscience Inc (OTCMKTS:NMUS) increased 14.78% closed at $0.310 and traded with total volume of 132,065.00 shares, while the average trading remained 251,736.00 shares. During last trade its minimum price was $0.27 and it gained the highest price of $0.31. Its market capitalization was $7.89 billion.
Nemus Bioscience Inc (NMUS) on March 22, 2017 announced that bactericidal synergy was achieved against multiple species of methicillin-resistant Staphylococcus aureus (MRSA) utilizing a proprietary cannabinoid-based therapeutic platform. MRSA species tested included community acquired- (CA-MRSA), healthcare-acquired- (HA-MRSA), and mupirocin-resistant (MR-MRSA) strains of MRSA.
In vitro studies demonstrated that when using unique strategic cannabinoid-based cocktails, fractional-inhibitory concentration (FIC) levels demonstrating synergy between mixtures of individual cannabinoid-based components ranged from 0.06 to 0.28. FIC findings below 0.5 indicate significant killing potential of the mixture.
“This work highlights the importance of Nemus’ relationship with the University which has significant experience and intellectual capital related to cannabinoid chemistry and physiology, dating back to 1968,” stated Brian Murphy, M.D., C.E.O. and Chief Medical Officer of Nemus. “These unique botanically derived components establish an anti-infective platform which could potentially be expanded into other types of bacteria, as well as viruses, and fungi.”
Dr. Mahmoud ElSohly, professor at the National Center for Natural Products Research (NCNPR) at the University of Mississippi commented: “The University, in conjunction with Nemus, is looking to expand the anti-infective capabilities of this series of compounds. Historically, many types of anti-infective compounds are derived from plants so to have a series of cannabinoid-related compounds exhibit activity against this dangerous pathogen is in keeping with prior efforts of drug development. I believe that these compounds, in addition to the bacterial killing capability, could also offer benefits associated with anti-inflammatory and anti-fibrotic properties that could enhance healing, especially against an organism associated with skin and soft tissue infections.”
Earth Science Tech Inc (OTCMKTS:ETST) reported the plunge of -6.25% and closed at $1.50, with the total traded volume of 12,266.00 shares. During last trade its minimum price was $1.38 and it gained its highest price of $1.61 and has a total of 40.91 million outstanding shares.
On March 6, 2017 Earth Science Tech, Inc. (ETST), an innovative biotech company focused on cannabis (industrial hemp) and cannabinoid research and development, nutraceuticals, pharmaceuticals, and medical devices based company is proud to announce that its wholly owned subsidiary Cannabis Therapeutics timeline for its cannabis cannabinoid-based nutraceutical patent and generic pharmaceutical drug completion.
At a meeting with the company’s Advisory Board on Tuesday, February 28th at Le Centre Québecois d’Innovation en Biotechnologie (CQIB) in Laval, Québec; the scientists concluded that the improved CBD Hemp Oil food supplement was ready to move to prototyping, and then to be fast tracked to commercialization. In addition, two cannabinoid-based generic pharmaceutical drugs will be ready for pre-market clinical trials related to drug bioavailability by Q3 2017. Depending on the time needed to properly conduct the clinical trials, both of the pharmaceutical drugs looks to be completed by the end of 2017 or beginning of 2018.
The first or these two generic drugs, an anti-breast cancer drug, is an important advance for the company as breast cancer affects more women worldwide than any other cancer. The components of the anti-breast cancer drug that Cannabis Therapeutics is bringing to market are contained in the World Health Organization’s current Model List of Essential Medicines (2015). The WHO Model Complementary List indicates the essential medicines needed to treat priority diseases, such as breast cancer, by any healthcare system.